GlassScriptPhysician profile
Josh A Hammel
NPI 1205123296
$7,556.52
in general payments reported to CMS, 2019-2025
28 companies · $838 in 2025
The $838 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $1,278 · 2021: $792 · 2022: $791 · 2023: $2,117 · 2024: $1,310 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.99 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,639.95 | 2023-2024 | Zoryve |
| Abbvie INC. | $1,221.65 | 2019-2025 | |
| Janssen Biotech, INC. | $765.13 | 2019-2024 | Tremfya |
| Genzyme Corporation | $525.16 | 2022-2025 | |
| Dermavant Sciences, INC. | $401.45 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $394.27 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $373.78 | 2019-2022 | |
| Galderma Laboratories, L.P. | $313.80 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $305.22 | 2022-2025 | Adbry |
| Pfizer INC. | $247.25 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $239.10 | 2024-2025 | Tremfya |
| Organon LLC | $237.32 | 2025 | Vtama |
| Amgen INC. | $205.59 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $113.99 | 2020-2021 | |
| Lilly USA, LLC | $100.22 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $88.12 | 2019-2023 | |
| Organogenesis INC. | $70.77 | 2021-2023 | Puraply |
| Regeneron Healthcare Solutions, INC. | $61.67 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $41.45 | 2020 | |
| Dusa Pharmaceuticals, INC. | $35.92 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.09 | 2020 | |
| Kerecis Limited | $34.83 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Surgiclose, Kerecis Omega3 Graftguide |
| Ucb, INC. | $24.60 | 2021 | |
| Dermira, INC. | $22.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.34 | 2021 | |
| Botanix Sb INC | $18.08 | 2025 | Sofdra |
| Celgene Corporation | $14.25 | 2019 | |
| Glenmark Therapeutics INC. | $5.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Hammel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.